Hyperpolarized Magnetic Resonance at the point-of-care
HYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods.
Projectdetails
Introduction
HYPMET proposes a pioneering research methodology for hyperpolarized magnetic resonance for real-time monitoring of upregulated metabolic pathways in cancer cells and in-vivo, as well as for body fluid metabolic analyses with the prospect of revolutionizing the medical approach to personalized treatments.
Background
A common analytical method for structural biology, medical imaging, and chemical analysis is nuclear magnetic resonance (NMR), which is flexible but intrinsically insensitive. Even in the most sensitive NMR spectra, many endogenous compounds found in blood, saliva, or urine are currently unresolved.
Objectives
HYPMET will establish a ground-breaking technology enabling the detection of body fluids metabolites below the current limit of NMR detection (~μM) and the real-time monitoring of clinically relevant metabolic pathways in-cells and in-vivo.
Key Features
- Enable NMR metabolomics analyses at the point-of-care.
- Fully compatible with personalized medical treatments.
- Compact design (less than 10×10×30 cm).
- No requirement for superconducting magnets.
Methodology
Emerging methods (e.g., hyperpolarization methods - HM) can boost the NMR signal intensity. HYPMET will merge two HMs to achieve NMR signal enhancements of several thousand-fold continuously, in the liquid state and at ultra-low magnetic field (ULF, i.e., <10 mT) for many nuclear isotopes.
The Two HMs
- Overhauser Dynamic Nuclear Polarization (ODNP)
- Signal Amplification By Reversible Exchange (SABRE)
Expertise and Implementation
The Principal Investigator's unique expertise spans method development on various HMs and the development and implementation of a protocol for real-time monitoring of pyruvate to lactate conversions in-cells and in-vivo to probe the state of a tumor in real-time.
Future Prospects
Success in this multidisciplinary project will pave the way for efficient NMR metabolomics analyses and for better real-time metabolic conversion monitoring directly at the point-of-care. In the future, the technology could be further reduced in size and become a widespread clinical tool.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.499.968 |
Totale projectbegroting | € 1.499.968 |
Tijdlijn
Startdatum | 1-5-2024 |
Einddatum | 30-4-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI PADOVApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Transportable Hyperpolarization for ImagingThis project aims to democratize hyperpolarization in NMR and MRI by using phase separation to extend the lifetimes of hyperpolarized agents for easier transport and broader accessibility. | ERC Proof of... | € 150.000 | 2024 | Details |
Inexhaustible Spring of Hyperpolarization For Magnetic ResonanceHypFlow aims to revolutionize NMR by developing a system for inexhaustible, pure hyperpolarization, enhancing sensitivity 10,000-fold for diverse applications in research and industry. | ERC Consolid... | € 2.990.000 | 2023 | Details |
Valorising magnetometry in cellsThis project aims to commercialize diamond magnetometry for measuring free radical generation in living cells, potentially leading to a startup focused on innovative diagnostic solutions. | ERC Proof of... | € 150.000 | 2022 | Details |
Radiation-detected NMR: new dimension for Magnetic Resonance spectroscopy and imagingThis project aims to develop a modular insert for conventional NMR and MRI spectrometers to enhance sensitivity through in-situ polarisation of longer-lived nuclei using radiation-detected NMR. | ERC Proof of... | € 150.000 | 2023 | Details |
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip PlatformsLIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes. | ERC Starting... | € 2.499.318 | 2025 | Details |
Transportable Hyperpolarization for Imaging
This project aims to democratize hyperpolarization in NMR and MRI by using phase separation to extend the lifetimes of hyperpolarized agents for easier transport and broader accessibility.
Inexhaustible Spring of Hyperpolarization For Magnetic Resonance
HypFlow aims to revolutionize NMR by developing a system for inexhaustible, pure hyperpolarization, enhancing sensitivity 10,000-fold for diverse applications in research and industry.
Valorising magnetometry in cells
This project aims to commercialize diamond magnetometry for measuring free radical generation in living cells, potentially leading to a startup focused on innovative diagnostic solutions.
Radiation-detected NMR: new dimension for Magnetic Resonance spectroscopy and imaging
This project aims to develop a modular insert for conventional NMR and MRI spectrometers to enhance sensitivity through in-situ polarisation of longer-lived nuclei using radiation-detected NMR.
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip Platforms
LIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Early detection of treatment response in breast cancerThe project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects. | EIC Transition | € 2.499.229 | 2024 | Details |
Hyperpolarized NMR made simpleMAGSENSE aims to enhance NMR sensitivity by using standard hydrogen molecules as polarization batteries, enabling ultrasensitive analysis without modifying existing equipment, thus revolutionizing various fields. | EIC Transition | € 2.451.913 | 2023 | Details |
Magnetic Resonance at the Scale of a CellThe HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses. | EIC Transition | € 1.998.750 | 2024 | Details |
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic careMIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally. | EIC Transition | € 2.495.127 | 2022 | Details |
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic InterventionsMITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs. | EIC Transition | € 2.100.238 | 2022 | Details |
Early detection of treatment response in breast cancer
The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.
Hyperpolarized NMR made simple
MAGSENSE aims to enhance NMR sensitivity by using standard hydrogen molecules as polarization batteries, enabling ultrasensitive analysis without modifying existing equipment, thus revolutionizing various fields.
Magnetic Resonance at the Scale of a Cell
The HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses.
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.